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Abstract
Background: Neuroinflammation and a systemic inflammatory reaction are important features of perinatal asphyxia.
Neuroinflammation may have dual aspects being a hindrance, but also a significant help in the recovery of the CNS.
We aimed to assess intracellular cytokine levels of T-lymphocytes and plasma cytokine levels in moderate and severe
asphyxia in order to identify players of the inflammatory response that may influence patient outcome.
Methods: We analyzed the data of 28 term neonates requiring moderate systemic hypothermia in a single-center
observational study. Blood samples were collected between 3 and 6 h of life, at 24 h, 72 h, 1 week, and 1 month of life.
Neonates were divided into a moderate (n = 17) and a severe (n = 11) group based on neuroradiological and amplitude-
integrated EEG characteristics. Peripheral blood mononuclear cells were assessed with flow cytometry. Cytokine plasma
levels were measured using Bioplex immunoassays. Components of the kynurenine pathway were assessed by high-
performance liquid chromatography.
Results: The prevalence and extravasation of IL-1b + CD4 cells were higher in severe than in moderate asphyxia at 6 h.
Based on Receiver operator curve analysis, the assessment of the prevalence of CD4+ IL-1β+ and CD4+ IL-1β+ CD49d+
cells at 6 h appears to be able to predict the severity of the insult at an early stage in asphyxia. Intracellular levels of
TNF-α in CD4 cells were increased at all time points compared to 6 h in both groups. At 1 month, intracellular levels of
TNF-α were higher in the severe group. Plasma IL-6 levels were higher at 1 week in the severe group and decreased by
1 month in the moderate group. Intracellular levels of IL-6 peaked at 24 h in both groups. Intracellular TGF-β levels
were increased from 24 h onwards in the moderate group.
Conclusions: IL-1β and IL-6 appear to play a key role in the early events of the inflammatory response, while TNF-α
seems to be responsible for prolonged neuroinflammation, potentially contributing to a worse outcome. The assessment
of the prevalence of CD4+ IL-1β+ and CD4+ IL-1β+ CD49d+ cells at 6 h appears to be able to predict the severity of the
insult at an early stage in asphyxia.
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Background
Neonatal asphyxia evokes the injury of the central ner-
vous system (CNS) due to the severe lack of oxygen and
perfusion during labor and delivery, resulting in moder-
ate to severe neurological dysfunction. Asphyxia primar-
ily affects term and post-term neonates. It occurs in 2–4
of every 1000 live-born term neonates and is responsible
for approximately 23% of neonatal deaths worldwide [1].
While some surviving children show favorable neuro-
logical outcome, others sustain severe neurodevelop-
mental disabilities such as mental retardation, sensory
impairment, cerebral palsy, and seizures [2]. Identifying
the factors responsible for such extent of individual vari-
ability regarding outcome would be critical; however, to
date, no definitive predictive factors have been validated.
Inflammation of the CNS, or neuroinflammation, is
now recognized to be a feature of all neurological disor-
ders, including that related to neonatal asphyxia. Micro-
glia and astrocytes become activated and release pro-
inflammatory cytokines and chemokines. Disruption of
the blood-brain barrier allows infiltration of peripheral
monocytes into the brain that further enhances the in-
flammatory response, leading to neuronal injury and
apoptosis. However, the inflammatory reaction following
asphyxia is not limited to the CNS, but can also be
detected in the periphery. Systemic immune activation is
characterized by increased synthesis of pro-
inflammatory cytokines [3]. A key player in the medi-
ation of the inflammatory response both in the brain
and peripheral blood during asphyxia is the subset of T
lymphocytes. T lymphocytes have a pivotal role in the
evolution of hypoxic injury. The mechanisms by which
T cells are neurotoxic include the production of perforin
and granzyme B, the release of free radicals, the trigger-
ing of apoptotic pathways within neurons, and most im-
portantly, the production of pro- and anti-inflammatory
cytokines [4, 5].
An extensive dataset describes neuroinflammation to
have detrimental consequences, but results have indi-
cated over the past decade that some aspects of the in-
flammatory response are beneficial for the CNS
outcomes [6, 7]. Benefits of neuroinflammation include
neuroprotection, the mobilization of neural precursors
for repair, remyelination, and axonal regeneration. In
vitro studies demonstrated that pro-inflammatory cyto-
kines, such as TNF-α and IFN-γ, are toxic for oligoden-
drocytes [8–10]. Although inflammatory cytokines
contribute to injury progression, they also play a vital
role in the fast elimination of cellular debris, and in the
processes of growth and repair, contributing to func-
tional recovery [11, 12]. The results of Saliba et al. sup-
port the positive role of certain cytokines in neuronal
regeneration [13]. In addition to its toxic effect, TNF-α
also plays a role in neuronal progenitor cell proliferation,
lineage commitment, and cellular differentiation. IL-1
also has neurotrophic properties which might be medi-
ated by the stimulation of nerve growth factor produc-
tion. Direct intracerebral injection of IL-1 or TNF-α has
been shown to stimulate astrogliosis and angiogenesis in
the developing rodent brain [14]. The TGF-β family con-
sists of pleiotropic proteins with potent immunoregula-
tory properties, which might also play key roles in the
development, repair, and survival of neurons [13].
Previous investigations in asphyxia demonstrated that
pro-inflammatory IL-1β, TNF-α, and IFN-γ play an out-
standing role in the pathophysiology. IL-6, IL-8, and
IL-17 (Th17 cells) also have an important contribution
[13, 15–17]. On the other hand, anti-inflammatory
TGF-β and IL-10 have a protective role and are import-
ant for regenerative processes [18]. Prolonged moderate
hypothermia improves neurological outcome and has be-
come standard care for term infants with hypoxic-
ischemic encephalopathy over the recent years [19]. One
mechanism by which hypothermia exerts a neuroprotec-
tive effect may be by reducing systemic inflammation
[20]. In an earlier study, we measured cytokine levels at
the 6th, 12th, and 24th postnatal hours in neonates with
asphyxia treated with hypothermia or standard intensive
care on normothermia [21]. Our results indicated that
IL-6 levels (at 6 h of age) and IL-4 levels (at all time
points) were significantly lower in asphyxiated neonates
treated with hypothermia compared to normothermic
neonates. The duration of hypothermia initiated before
6 h of age correlated with lower levels of IL-6, TNF-α,
and IFN-γ measured at 6 h of age. These data suggest
that therapeutic hypothermia may rapidly suppress and
modify the immediate cytokine response in asphyxia.
The permeability of the BBB is higher in neonates
compared to adults and is further disrupted by the hyp-
oxic injury itself. The release of IL-1β, TNF-α, and IFN-γ
also increase the permeability of the BBB [22, 23].
CD49d is part of the VLA-4 antigen which mediates the
migration of activated leukocytes to the site of tissue
inflammation via binding to VCAM-1, expressed by
endothelial cells [24]. VLA-4 is thus crucial for the mi-
gration of activated T lymphocytes through the BBB to
the site of inflammation in the brain [25, 26], making it
a primary therapeutic target in multiple sclerosis [27]
and in primary neuroinflammatory brain disease in mur-
ine ischemic stroke models [28]. Although VCAM-1 is
not exclusively expressed in the CNS, the level of
CD49d expression can be correlated with the capacity of
T lymphocytes to enter the site of inflammation, more
specifically the brain tissue in the case of neuroinflam-
mation [29].
The interplay between the kynurenine system and
cytokines is a regulator of both innate and adaptive im-
mune responses, and it plays an important role in the
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interactions between the central nervous and the im-
mune systems [30, 31]. Indoleamine 2,3-dioxygenase
(IDO), the rate-limiting enzyme in the degradation of
tryptophan, plays a central role in regulating these inter-
actions. IDO degrades TRP to kynurenine (KYN), which
is then metabolized by the enzymes within the kynure-
nine pathway into other catabolites, such as Kynurenic
acid (KYNA). While some TRP metabolites may have
neurotoxic potential, KYNA appears to be a potent neu-
roprotective agent as it ameliorates NMDA receptor-
mediated excitotoxicity [32] and acts as a potent free
radical scavenger and endogenous antioxidant [33].
Induced by pro-inflammatory stimuli (such as IFN-γ),
IDO is primarily produced by antigen presenting cells
(APCs) and has several immunosuppressive effects, thus
maintaining the balance between pro- and anti-
inflammatory impulses. The rate of TRP degradation,
expressed by the ratio of KYN to TRP (K/T), allows a
good estimate of its enzymatic activity [34]. The induc-
tion of IDO and the kynurenine system results in the in-
hibition of T cell functions, the activation of regulatory
T cells, and the inhibition of natural killer cells. The al-
terations of the kynurenine system appear to play a role
in the pathophysiology of a broad spectrum of neuro-
logical disorders [35], including ischemic brain injury;
however, its role has previously not been investigated in
perinatal asphyxia.
The challenge in neonatal asphyxia is to harness the
beneficial aspects of neuroinflammation following the in-
sult to allow neuroprotection and regeneration within the
CNS while at the same time minimizing its harmful ef-
fects. Significant barriers remain in understanding the
benefits of inflammation in contrast to its detriments fol-
lowing neonatal asphyxia. Identification of factors that dif-
ferentiate between infants with an extensive and
potentially damaging neuroinflammatory response and in-
fants with moderate inflammation would present new op-
tions for a more individualized therapeutic approach in
neonatal asphyxia. In this study, we aimed to assess the
prevalence and cytokine production of T lymphocyte sub-
sets in moderate and severe perinatal asphyxia in order to
identify players of the inflammatory response that may in-
fluence patient outcome. In contrast to previous studies,
we aimed to determine the intracellular cytokine levels of
T lymphocytes besides plasma cytokine levels. We also
aimed to describe plasma TRP, KYN, and KYNA levels.
We also expanded our investigation to 1 month of age fol-
lowing the CNS insult to understand longer-term conse-
quences of the hypoxic event.
Methods
Patients
We enrolled 33 term neonates admitted to the regional
neonatal intensive care unit at the First Department of
Pediatrics at Semmelweis University, Budapest, Hungary,
with the initial diagnosis of perinatal asphyxia requiring
therapeutic hypothermia. The diagnosis of moderate-to-
severe hypoxic-ischemic encephalopathy and the
eligibility for cooling was assessed according to the
TOBY criteria [36]. Infants fulfilled both criteria A
(Apgar score ≤ 5 at 10 min after birth OR continued
need for resuscitation, including endotracheal or mask
ventilation, at 10 min after birth OR umbilical cord,
arterial, or capillary pH < 7.00 within 60 min of birth OR
base deficit ≥ 16 mmol/L in umbilical cord or any blood
sample (arterial, venous, or capillary) within 60 min of
birth) AND criteria B (clinical seizures OR altered state
of consciousness (reduced response to stimulation or ab-
sent response to stimulation) AND abnormal tone (focal
or general hypotonia, or flaccid) AND abnormal primi-
tive reflexes (weak or absent suck or Moro response)).
All enrolled neonates were outborn, and hypothermia
was initiated between 1 and 5 h of life (mostly within
2 h of life as hypothermia was started before and main-
tained during transport). Rectal temperature was main-
tained between 33 and 34 °C and was recorded every
hour during the 72 h intervention period. Two-milliliter
venous blood samples were collected between 3 and 6 h
of life (at admission), as well as at 24 h, 72 h, and 1 week
of life during intensive care treatment, adjusted to blood
sampling related to clinical care. A further venous blood
sample was obtained at 1 month of age during a routine
outpatient follow-up appointment.
Neonates with congenital abnormalities or CNS mal-
formations, maternal chorioamnionitis or perinatal in-
fections were excluded from the study. Blood cultures
and ear swabs were obtained at admission from all in-
fants, and bacterial infection was excluded. Clinical or
culture-proven sepsis was not detected in any of the par-
ticipating infants. All infants received regular preventive
intravenous antibiotics, i.e., ampicillin and gentamicin,
during the hypothermic treatment. Four infants were ex-
cluded from the analysis as their MRI scan results
showed signs of neonatal stroke rather than a hypoxic-
ischemic insult. One further infant was excluded due to
suspected metabolic disease (peroxisomal fatty acid C26/
C22 ratio above the normal range) as well as the pres-
ence of multiple minor anomalies and mutation of the
ROBO1 gene. Therefore, data from 28 neonates are ana-
lyzed in this study. Participating neonates were divided
into two groups based on the severity of hypoxic-
ischemic insult, determined by initial and recovery time
of amplitude-integrated EEG (aEEG) monitoring [37] as
well as MRI results performed up to 12 days of life. MRI
data were interpreted by radiologists who were blinded
to the clinical status of the neonates, based on the
criteria defined by Marcovici et al. and Bosmans et al.
[38, 39]. The reporting template was developed in the
Bajnok et al. Journal of Neuroinflammation  (2017) 14:244 Page 3 of 14
ISORT (intelligent structured online reporting tool) soft-
ware framework created by Bioscreen Ltd., Debrecen,
Hungary. In cases where MRI was not performed due to
the critical condition of the patient or MRI data were
missing, grouping was done solely based on the aEEG
results. The severe group (n = 11) consisted of newborns
with moderate-to-severe hypoxic-ischemic encephalop-
athy (HIE) signs on MRI scans AND burst-suppression
or continuous extremely low voltage or flat tracing
background activity on aEEG OR normalization of
aEEG after the 48th hour of life or never, OR early
death (< 28 days). Neonates that met none of the above-
listed criteria constituted the moderate group (n = 17)
(normal MRI scans or mild HIE signs on MRI scans AND
continuous or discontinuous normal voltage background
activity on aEEG OR normalization of aEEG activity
before the 48th hour of life).
In the severe group, three infants deceased before
1 month of age due to the severity of the insult. Avail-
able data from these neonates were included at the
relevant time points within the severe group. Therefore,
72-h, 1-week, and 1-month data were missing in case
of two infants, and 1-month data were missing from
one infant.
Our study was reviewed and approved by the Hungarian
Medical Research Council (TUKEB 6578-0/2011-EKU),
and written informed consent was obtained from parents
of all participants. The study was adhered to the tenets of
the most recent revision of the Declaration of Helsinki.
Clinical characteristics and laboratory parameters of par-
ticipants are summarized in Table 1.
Flow cytometry
Plasma was separated from peripheral blood samples by
centrifugation. Plasma samples were aliquotted and im-
mediately frozen and stored at − 80 °C for later deter-
mination of cytokine concentrations and HPLC
measurements.
Remaining cells were resuspended in RPMI (Roswell
Park Memorial Institute)-1640 medium (Sigma-Aldrich,
St. Louis, MO, USA). Cells were incubated with PMA
(phorbol 12-myristate 13-acetate) (50 ng/ml), ionomycin
(1 μg/mL), and BFA (brefeldin A) (10 μg/ml) for 6 h at
37 °C to allow intracellular accumulation of cytokines.
For surface marker staining, samples were then
incubated with the following fluorochrome-conjugated
anti-human monoclonal antibodies: CD4 PE-Cy7
(phycoerythrin-cyanine 7) and CD8 APC-Cy7 (allophy-
cocyanin-cyanine 7) (panel 1) or CD4 APC-Cy7 and
CD49d PerCP (peridinin-chlorophyll-protein) (panel 2),
respectively, according to the manufacturers’ instruc-
tions (all from BioLegend, San Diego, CA, USA). Red
blood cells were lysed and PBMCs were permeabilized
using FACSLysing and FACSPermeabilizing solutions
(BD Biosciences, San Jose, CA, USA). Cells were washed
and resuspended in PBS (phosphate buffer saline) and
divided into two equal aliquots and stained according to
the manufacturers’ instructions for intracellular cyto-
kines using the following conjugated anti-human mono-
clonal antibodies or the appropriate isotype controls:
IL-6 PE (phycoerythrin), IL-17A PerCP, IL-10 APC
(allophycocyanin), and IFN-γ FITC (fluorescein isothio-
cyanate) (for panel 1) or TNF-α PE-Cy7, FoxP3 PE,
TGF-β APC, and IL-1β FITC (for panel 2), respectively
(all from BioLegend). Following labeling, cells were
washed and resuspended in PBS for flow cytometry ana-
lysis. Samples were analyzed immediately on a FACSAria
flow cytometer (BD Biosciences) equipped with 488 and
633 nm excitation lasers. Data were processed using the
FACSDiVa software (BD Biosciences). One hundred thou-
sand cells were recorded. Evaluators of flow cytometry
data were blinded to the clinical status of the neonates.
Table 1 Clinical characteristics of neonates in the moderate and
severe groups upon admission (within 12 h of age)
Moderate group
(n = 17)
Severe group
(n = 11)
Male gender (%) 10 (59) 7 (64)
Birthweight (g) 3330 (2860–3605) 3000 (2490–3300)
Gestational age (week) 39 (37–40) 38 (37–40)
No. of C-sections (%) 10 (59) 8 (73)
Apgar at 1 min 3 (0.5–4.5) 1 (0–3)
Apgar at 5 min 6 (5–7) 2* (0–4)
Apgar at 10 min 7 (5–8) 4* (1.75–5.25)
Worst pH (within first 12 h) 7.025 (6.874–7.12) 6.86 (6.62–7.058)
Worst BD (within first 12 h)
(mmol/L)
18.05 (16.65–21.275) 20.4 (19.375–23.5)
Need for inotropes (%) 8 (44) 8* (73)
Need for hydrocortisone (%) 5 (36) 5 (45)
Need for erythrocyte
transfusion (%)
7 (41) 4 (36)
Need for platelet
transfusion (%)
2 (11) 1 (9)
Need for fresh
frozen plasma (%)
6 (35) 10* (91)
S100 (ug/L) 7.48 (2.33–28.85) 21.8 (3.8–30.0)
LDH (U/L) 2072 (1371–5274) 3335 (1879–5792)
Uric acid (umol/L) 530 (474.5–576.5) 593 (443–634)
AST (U/L) 112 (79–363) 207 (128–438)
ALT (U/L) 24 (19–125) 54 (29–148)
GGT (U/L) 123 (73–198) 97 (47–197)
Urea (mmol/L) 4.9 (3.7–5.3) 4.8 (3.9–5.7)
Creatinine (umol/L) 88 (78.5–99) 105 (80–114)
Data are presented as median (IQR)
*p < 0.05 vs Moderate group
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Immunoassays
Plasma samples were stored at − 80 °C until analysis.
The plasma levels of the following cytokines, chemo-
kines, and growth factors were determined using Bio--
Plex Pro Assays (Bio-Rad Laboratories, Hercules, CA,
USA): IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
12, IL-13, IL-17, IFN-γ, TNF-α, TGF-β, G-CSF, GM-CSF,
MCP-1, MIP-1b, and VCAM. Bio-Plex Pro Assays are
immunoassays formatted on magnetic beads that utilize
principles similar to those of a sandwich ELISA. Capture
antibodies against the biomarker of interest are cova-
lently coupled to the beads. A biotinylated detection
antibody creates the sandwich complex, and the final de-
tection complex is formed by the addition of a
streptavidin-phycoerythrin (SA-PE) conjugate, where PE
serves as the fluorescent reporter. Reactions are read
using a Luminex-based reader.
High-performance liquid chromatography
Plasma samples were stored at − 80 °C until analysis.
Directly prior to analysis, samples were thawed, vortexed,
and 300 μl of plasma was “shot” onto 700 μl of precipita-
tion solvent (containing 3.57 w/w% perchloric acid and
2.857 mM 3-nitro-L-tyrosine as internal standard
(Scharlau, Barcelona, Spain)). Samples were then centri-
fuged (13,000 g for 10 min at 4 °C), and the supernatants
were collected. For the quantification of KYN, KYNA, and
TRP concentrations of samples, a modified method based
on Herve et al. [40] was utilized, using an Agilent 1100
HPLC system (Agilent Technologies, Santa Clara, CA,
USA). The system was equipped with a fluorescent de-
tector, which was used to determine the concentration of
KYNA and TRP, and a UV detector which was applied for
the determination of KYN and the internal standard.
Chromatographic separations were performed on an Onyx
monolithic C18 column, 100 × 4.6 mm I.D. (Phenomenex
Inc., Torrance, CA, USA) after passage through a Hypersil
ODS precolumn, 20 × 2.1 mm I.D., 5-μm particle size
(Agilent Technologies) with a mobile phase composition
of 0.2 M zinc acetate/acetonitrile 95/5 v/v% with a pH
adjusted to 6.2 with glacial acetic acid, applying isocratic
elution. The flow rate and the injection volume were
1.5 mL/min and 20 μL, respectively. The fluorescent de-
tector was set at excitation and emission wavelengths of
344 and 398 nm, and after 3.5 min of each run, the wave-
lengths were changed to 254 and 398 nm. The UV de-
tector was set at a wavelength of 365 nm. L-TRP, L-KYN
sulfate salt, KYNA, and zinc acetate dihydrate were pur-
chased from Sigma-Aldrich, and acetic acid was
purchased from VWR International (Radnor, PA, USA).
Statistical analysis
Data are expressed as median and interquartile range.
Comparisons between sample populations were
performed with Mann-Whitney tests, as a test of nor-
mality (performed according to Kolmogorov-Smirnoff )
indicated the non-normal distribution of data. Compari-
sons between the paired values (samples collected at
different time points) in the same population were made
with Friedman tests. p values less than 0.05 were consid-
ered significant. Outliers were identified using Grubbs’
tests and were excluded from the analyses. Statistics
were calculated using the GraphPad Prism 5 software
(La Jolla, CA, USA).
Results
IL-1β
Our results suggest that CD4+ IL-1β+ cells are early me-
diators of the inflammatory response, as their prevalence
is higher at 6 h after birth in severe compared to moderate
asphyxia. The extravasation of these cells is also increased
at this time point in severe asphyxia as evidenced by the
lower prevalence of CD49d-expressing CD4+ IL-1β+ cells
in peripheral blood. Therefore, although plasma levels of
IL-1β are not different in moderate and severe asphyxia,
IL-1β may play an important role in initiating tissue dam-
age in the brain following the hypoxic insult. Intracellular
(MFI) levels of IL-1β in both groups and plasma levels in
the moderate group are highest at 6 h and comparably
lower at the following time points, suggesting that its
main role is the initiation of the inflammatory response
(Table 2 and Figs. 1 and 2).
IL-6
Plasma IL-6 levels were higher at 1 week in the severe
compared with the moderate group. Plasma IL-6 levels
decreased by 1 month following the insult in the moder-
ate group. Mean fluorescence intensity (MFI) of CD4+
IL-6+ cells peaked at 24 h in both patient groups and
declined later, indicating that it may play a role in the
initial inflammatory response. MFI of CD8+ IL-6+ cells
in the severe group also decreased by 1 week (Table 2
and Figs. 1 and 2).
IL-17
The prevalence of CD8+ IL-17+ cells was higher in the
moderate group than in the severe group at 6 h. In con-
trast, the prevalence of CD4+ IL-17+ cells was lower in
the moderate than in the severe group at 1 week The
prevalence of CD4+ IL-17+ was lower at 6 h than at other
time points in the severe group and remained high until
1 month. MFI of CD8+ IL-17+ cells at 24 h and that of
CD4+ IL-17+ cells at 72 h were also higher in the severe
group. The MFI of CD8+ IL-17+ cells peaked at 72 h in
the moderate group. No difference was observed in
plasma levels of IL-17 (Table 2 and Figs. 1 and 3).
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TNF-α
On the contrary, MFI of TNF-α in CD4 cells was in-
creased at all time points compared to 6 h in both groups.
At 1 month, MFI of TNF-α was higher in the severe
group, suggesting that it might play a role in the develop-
ment of long-term consequences of asphyxia. The preva-
lence of CD49d-expressing CD4+ TNF-α+ cells is lower
in severe asphyxia at 6 h compared to later time points,
indicating that in a severe insult, it might also contribute
to early tissue destruction through increased extravasa-
tion. This is further supported by the fact that the preva-
lence of CD49d-expressing CD4+ TNF-α+ cells is lower at
6 h and higher at 72 h in severe asphyxia compared to a
moderate insult. No difference was observed in plasma
levels of TNF-α (Table 2 and Figs. 1 and 3).
Other pro-inflammatory cytokines
MFI of CD4+ IFN-γ+ cells was higher in the severe than
in the moderate group at 72 h. Plasma MCP-1 levels
were higher at 24 and 72 h as well as 1 week than at 6 h
in the moderate group. Plasma G-CSF levels were higher
at 24 h and 1 week in the severe compared with the
moderate group. G-CSF levels decreased by 1 week and
remained low at 1 month following the initial insult in
the moderate group (Table 2 and Fig. 2).
TGF-β
The prevalence of CD49d-expressing CD4+ TGF-β+
cells was increased at 1 week and 1 month compared to
72 h in the moderate group potentially indicating that
TGF-β plays an anti-inflammatory role in tissue regener-
ation in the early stage of the insult. MFI of CD4+
TGF-β+ cells was increased from 24 h onwards in the
moderate but not in the severe group, which is probably
also part of a compensatory phenomenon (Figs. 1 and 3).
Other anti-inflammatory cytokines
Plasma IL-10 levels were lower at 1 month than at 6 and
24 h in the moderate group. Plasma IL-13 and IL-5
levels were higher in the moderate than in the severe
group at 72 h. Plasma IL-13 levels were higher at 6 and
24 h than the following time points in the severe group
(Table 2 and Fig. 2).
Tregs
The prevalence of Tregs is somewhat higher in severe
asphyxia at 24 h, which might be part of a compensatory
Table 2 Significant differences in intracellular cytokine, plasma cytokine, and high-performance liquid chromatography (HPLC) data
between the moderate and severe group
Time Moderate Severe
Intracellular cytokines—cell prevalence data (% of parent population)
CD4+ IL-1b+/CD4+ 6 h 3.52 (2.13–5.16) 6.77 (3.18–10.26)
CD4+ IL-1b+ CD49d+/CD4+ IL-1b+ 6 h 6.98 (4.61–9.32) 4.08 (2.86–5.46)
CD4+ TNF-a + CD49d+/CD4+ TNF-a+ 6 h 6.63 (4.47–13.45) 3.52 (2.12–7.23)
CD8+ IL-17+/CD8+ 6 h 5.26 (3.89–14.40) 2.63 (1.75–5.18)
CD4+ FoxP3+/CD4+ 24 h 2.35 (1.96–3.13) 3.02 (2.60–4.13)
CD4+ TNF-a+ CD49d+/CD4+ TNF-a+ 72 h 4.77 (3.43–7.70) 9.75 (6.31–10.80)
CD4+ IL-17+/CD4+ 1 week 3.08 (1.80–4.59) 5.13 (3.40–13.76)
Intracellular cytokines—mean fluorescence intensity (MFI) data (arbitrary unit)
CD8+ IL-17+/CD8+ 24 h 1069 (639–3265) 4187 (1274–6133)
CD4+ IFN-g+/CD4+ 72 h 455 (150–770) 887 (496–1427)
CD4+ IL-17+/CD4+ 72 h 939 (566–1674) 1760 (1614–3508)
CD4+ TNF-a+/CD4+ 1 month 3281 (1752–4326) 4729 (3959–6714)
Plasma cytokines (pg/mL)
G-CSF 24 h 19.85 (10.87–30.70) 42.74 (22.27–131.3)
IL-5 72 h 1.37 (0.00–4.69) 0.20 (0.00–0.46)
IL-13 72 h 2.35 (2.01–3.67) 1.70 (1.40–2.56)
IL-6 1 week 21.06 (11.89–43.24) 70.25 (33.73–134.1)
G-CSF 1 week 13.33 (5.52–17.72) 32.90 (16.65–94.76)
HPLC results (uM)
KYN 1 month 3.62 (2.72–4.47) 2.28 (1.45–3.14)
p < 0.05 for all comparisons
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mechanism; however, the biological significance of this
increase is questionable (Table 2).
The kynurenine system
Plasma KYN levels were higher at 1 month in the moder-
ate group compared to the severe group. KYN levels
showed a decline in both groups by 1 week and 1 month
following the insult. Similar results were observed for
KYNA, while TRP levels increased significantly by 1 month
in both groups. In line with the above, the K/T ratio, cor-
responding to the enzymatic activity of IDO, plummeted
by 1 month in both groups (Table 2 and Fig. 4).
ROC analysis
We performed ROC analyses to assess which parame-
ters have the potential to discriminate between a
moderate and a severe insult at an early stage. The
only significant results of the ROC analyses were
related to intracellular IL-1β. The prevalence of CD4+
IL-1β+ cells at 6 h (p = 0.018, ROC AUC = 0.784) and that
of CD4+ IL-1β+ CD49d+ cells at 6 h (p = 0.027, ROC
AUC = 0.767) was able to differentiate severity with a
reasonable sensitivity and specificity (Fig. 5).
Discussion
Several studies have described the importance of cyto-
kines in normal neuronal differentiation and survival
[41–43]. The perinatal brain might be particularly sus-
ceptible to alterations in cytokine concentrations, and
experimental data suggest that cytokines play a pivotal
role in the regulatory network orchestrating neuroin-
flammation [44]. Cytokines have been in the limelight of
research focusing on asphyxia. The inflammatory re-
sponse following hypoxic brain injury has been shown to
have dual effects. A certain level of inflammation ap-
pears to be necessary for the adequate regeneration of
the brain tissue [6], while extensive neuroinflammation
might contribute to further CNS injury and be an im-
portant factor in worse functional outcome. We aimed
therefore to determine factors that might differentiate
Fig. 1 Intracellular cytokine level alterations in time represented by mean fluorescence intensity (MFI) values in moderate and severe asphyxia. Horizontal
line, median; box, interquartile range; whisker, range. p < 0.05 a vs 6 h, b vs 24 h, c vs 72 h, d vs 1 week
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between infants who have an adequate level of inflam-
matory response which is necessary for neuroregenera-
tion from infants in whom the uncompensated
inflammatory response contributes to brain injury. Previ-
ous studies have focused on determining the level of cy-
tokines from plasma. However, plasma cytokine levels
have been shown to have a great variability compared
with intracellular cytokine levels, which closely reflect
cytokine production at a cellular level and show more
stable kinetics in time, and thus open new possibilities
for more precise characterization of the cytokine net-
work in immune disorders. The relationship between
cellular cytokine production and serum cytokine levels is
undefined; cytokines in the serum originate from various
different sources and show less stable kinetics. The
advantage of intracellular cytokine analysis by flow
cytometry is that with this method, the cytokine produc-
tion of each cell type can be accurately described. This
method opens up the opportunity for precise
characterization of the function of each cell type in a
physiological setting (i.e., maintaining autocrine and
cell-cell interactions), which could be of great value in
identifying key cellular players of various inflammatory
conditions [45, 46]. We therefore primarily aimed to
describe intracellular cytokine values; however, we
also measured cytokine levels from plasma to gain a
more comprehensive picture of the immunologic al-
terations following the hypoxic insult. Furthermore,
contrary to previous studies, we expanded sampling
of infants to 1 month of age to obtain data on
Fig. 2 Plasma cytokine level alterations in time in moderate and severe asphyxia. Horizontal line, median; box, interquartile range; whisker, range.
p < 0.05 a vs 6 h, b vs 24 h, c vs 72 h, d vs 1 week
Fig. 3 Cell prevalence data alterations in time in moderate and severe asphyxia. Horizontal line, median; box, interquartile range; whisker, range.
p < 0.05 a vs 6 h, b vs 24 h, c vs 72 h, d vs 1 week
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longer-term changes in inflammatory parameters
evoked by asphyxia.
IL-1β
IL-1β is an important mediator of pro-inflammatory re-
sponses [47] and has been reported to have neurotoxic
properties leading to BBB breakdown and apoptotic
neuronal death [48, 49]. Aly et al. found that the CSF
level of IL-1β in term neonates had the highest predict-
ive value of poor neurologic outcome in asphyxia after 6
and 12 months and suggested the central role of IL-1β
in the ongoing neuronal injury that occurs in the latent
phase following the original hypoxic insult [16]. They
also found a high CSF to plasma ratio of IL-1β, indicat-
ing elevated local production of the cytokine in the
CNS. Several animal models also suggest that IL-1β con-
tributes to the brain injury [50, 51]. The exacerbation of
ischemic brain injury has also been observed following
exogenous administration of IL-1β. Other studies
demonstrated that the deficiency of IL-1β converting en-
zyme or treatment with IL-1 receptor antagonists
(IL-1ra) resulted in the moderation of hypoxic brain
injury [52, 53], decreased post-ischemic edema [49], and
improved neurological outcome [54].
The primary sources of IL-1β are APCs and mono-
cytes [55, 56], although microglia and endothelial cells
are also capable of producing IL-1β [57, 58]. The fact
that T lymphocytes are able to produce physiologically
relevant amounts of IL-1β and that it plays an important
role in their functionality has only recently been revealed
[59]. In this study, we observed significant IL-1β produc-
tion in T lymphocytes in neonatal asphyxia, which was
more pronounced in a severe insult. In line with the pre-
vious findings [16], our current results suggest that CD4
+ IL-1β+ cells might play an important role in initiating
tissue damage in the brain following the hypoxic insult.
Fig. 4 Alterations in the components of the kynurenine pathway in time in moderate and severe asphyxia. Horizontal line, median; box, interquartile
range; whisker, range. KYN kynurenine, KYNA kynurenic acid, TRP tryptophan, K/T kynurenine/tryptophan ratio. p < 0.05 a vs 6 h, b vs 24 h, c vs 72 h, d
vs 1 week
Fig. 5 Receiver operator curve (ROC) analysis of the prevalence of CD4+ IL-1β+ and CD4+ IL-1β + CD49d+ cell subsets in moderate and severe
neonatal asphyxia. AUC area under the curve
Bajnok et al. Journal of Neuroinflammation  (2017) 14:244 Page 9 of 14
However, intracellular concentrations of IL-1β gradually
decreased in both patient groups, suggesting that a cer-
tain level of initial increase may be necessary for the
regenerative processes as well. Based on our ROC ana-
lysis, the prevalence of IL-1β-producing CD4+ T cells
may be useful in the differentiation of the severity of the
insult at an early stage, up to 6 h after birth (Fig. 5). The
notable amount of data showing the therapeutic benefits
of peripheral administration of IL-1ra following ischemic
brain injury [60] and the fact that IL-1 receptor antagon-
istic agents are already available in clinical use in auto-
immune disorders prompts further research to explore
whether IL-1β levels above a certain threshold may be a
potential future therapeutic target in neonatal asphyxia.
IL-6
Several previous studies have associated elevated IL-6
CSF levels with poor neurological outcome, cerebral
palsy, and death in asphyxia [44, 61]. However, Aly et al.
suggested that IL-6 might have neurotrophic as well as
neuroprotective, anti-inflammatory effects via inhibiting
the synthesis of TNF-α and IL-1β [16, 62]. They found
highly elevated IL-6 CSF to plasma ratios, and Martin-
Ancel et al. also concluded that IL-6 appears to be pri-
marily produced intrathecally following the ischemic
brain injury while diffusion from the plasma is secondary
[44]. In this study, we found that plasma IL-6 levels were
elevated in severe compared to moderate asphyxia at
1 week and decreased in moderate, but not in severe as-
phyxia by 1 month. Intracellular levels of IL-6 in CD4+
cells peaked at 24 h in both patient groups and declined
later. However, we found no alterations in intracellular
cytokine levels or cellular prevalence data between the
two study groups, suggesting that CSF levels of IL-6
might be of more importance with regard to its deleteri-
ous effects.
IL-17
IL-17 is a pro-inflammatory cytokine produced primarily
by Th17 cells upon IL-23 stimulation [63]. IL-17 has
been shown to play a pivotal role in the delayed progres-
sion of brain infarction following hypoxic injury in a
mouse brain ischemia model. This is further supported
by the fact that IL-17KO mice show a significant reduc-
tion in the infarcted area and apoptotic neuronal death
from the fourth post-stroke day onwards [64]. Yang et al.
reported a significant influx of Th17 cells into the brain
tissue in hypoxic-ischemic encephalopathy following
LPS (lipopolysaccharide)-sensitization both in neonates
and in newborn rats [65]. In line with the previous find-
ings in mouse models, we observed a delayed increase in
the prevalence and cytokine production of IL-17 produ-
cing T cells, which remained elevated in the severe
group during the whole observation period. The
prevalence of Th17 lymphocytes was higher in the se-
vere group than in the moderate group at 1 week. IL-17
could play an important role in maintaining the chronic
neuroinflammation leading to detrimental consequences.
TNF-α
TNF-α is a pro-inflammatory cytokine which stimu-
lates the production of IL-1β and among other cyto-
kines regulates the apoptosis of CNS cells, promotes
leukocyte differentiation, proliferation, and subsequent
CNS infiltration [66, 67]. There is an extensive
amount of data supporting the role of TNF-α in is-
chemic brain damage [52, 68–71]. The level of TNF-α
in the CNS has been shown to peak 6–12 h following
the hypoxic-ischemic injury in newborn rats [61].
Increased TNF-α and IL-1β plasma and CSF levels in
term infants with asphyxia have been associated with
neuroradiological alterations, poor neurological status
at 12 months of age, and cerebral palsy [72, 73].
Blocking TNF-α, for example, by the administration
of pentoxifylline, a competitive inhibitor of TNF-α,
improved neurological outcome by attenuating ICAM-
1 expression, reducing the disruption of the BBB and
protecting neurons from delayed cell death in animal
models of head trauma [74].
In line with the previous findings, we found that the
MFI of TNF-α in CD4 cells was increased in both
groups at all time points compared to 6 h, suggesting a
delayed increase in production of TNF-α by T cells fol-
lowing the insult. In severe asphyxia, we observed higher
MFI of TNF-α at 1 month than in moderate asphyxia,
which might indicate that TNF-α plays a role in main-
taining a chronic inflammatory response in severe as-
phyxia, thus contributing to long-term consequences.
We found increased extravasation of TNF-α producing
cells at 6 h (indicated by the decreased prevalence of
CD49d-expressing CD4+ TNF-α+ cells), which may
indicate the role of TNF-α in determining the extent of
the initial tissue injury as well. At later time points, we
found that the expression of CD49d increased on
TNF-α-producing CD4 cells in severe asphyxia, which
might further indicate the increased potential of these
cells to enter the CNS. Rothhammer et al. were able to
demonstrate that under Th1 differentiation promoting
circumstances, naive T cells (CD4+ CD44− FoxP3−) dif-
ferentiate into encephalitogenic T cells in approximately
3 days, expressing high amounts of CD49d in mice [75].
It is, therefore, possible that an initial decrease in the
prevalence of CD49d+ lymphocytes due to extravasation
is followed by differentiation of CD4+ CD49d+ lympho-
cytes from the naïve T lymphocyte pool, leading to an
increased prevalence of circulating CD49d+ cells as part
of an ongoing inflammatory response.
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Anti-inflammatory factors
In order to comprehensively assess the immunosuppres-
sive components of the adaptive immune system in neo-
natal asphyxia, we examined TGF-β levels, along with
the prevalence of Treg cells and the involvement of the
KYN pathway. TGF-β plays a critical role in immuno-
suppression both by inhibiting inflammatory cells and
promoting the function of Treg cells via inducing their
FoxP3 expression [76–82]. Activated Tregs then produce
large amounts of TGF-β, which acts as an important
autocrine signal in their activation [83]. TGF-β specific-
ally limits Th1 differentiation and expansion [84, 85]
without affecting Th2 effector function and suppresses
the production of pro-inflammatory cytokines, while
promoting the production of anti-inflammatory IL-10
[86]. Besides direct inhibition, Tregs also inhibit T cell
function by affecting the APC-T cell interactions, for ex-
ample via the CTLA-4 engagement-induced TRP catab-
olism by IDO [87, 88].
TGF-β is associated with the reparation of the infarcted
tissue and thus is expressed later than pro-inflammatory
cytokines [13]. Interestingly, we observed an elevation
after 24 h in the intracellular level of TGF-β in moderate
asphyxia that was not present following a severe insult,
where the level of TGF-β remained comparable to the 6 h
level throughout the whole observation period. We found
increased CD49d-expression, which indicates a higher po-
tential of TGF-β producing cells to enter the CNS at
1 week and 1 month compared to 72 h in the moderate
group. These findings suggest that TGF-β plays an im-
portant role in attenuating the inflammatory response and
in tissue regeneration following the hypoxic insult in mod-
erate asphyxia. The lack of this effect may contribute to a
more severe outcome. We found a moderately elevated
prevalence of Tregs in severe compared to moderate as-
phyxia at 24 h, which might be part of a compensatory
mechanism; however, the biological significance of this in-
crease is unremarkable.
Plasma KYN levels were higher at 1 month in the mod-
erate than in the severe group, which might contribute to
an immunosuppressive effect. KYN levels showed a de-
cline in both groups by 1 week following the insult (Fig. 4).
Similar results were observed for KYNA, while TRP levels
increased significantly by 1 month in both groups. In line
with the above, the K/T ratio, indicating IDO enzymatic
activity, plummeted by 1 month in both groups. This in-
creased activation of IDO and TRP catabolism in the post-
natal period (up to 1 week) appears to be part of a
regulatory mechanism that might play an important role
in attenuating the inflammatory response following the
hypoxic insult. This effect was comparable in moderate
and severe asphyxia, which could mean that this early
activation of the KYN pathway is part of the physiological
process that accompanies the neuroinflammatory re-
sponse. However, it appears that the importance of this
regulatory mechanism decreases by 1 month.
A limitation of our study is that we did not investigate
cell prevalence or cytokine levels in CSF samples.
Although this would have provided further data on the
local inflammatory response in the CNS, the collection of
CSF samples was not possible due to ethical consider-
ations in the lack of clinical indication. A further limita-
tion of this study is the fact that five neonates in each
study group (Table 1) received hydrocortisone during in-
tensive care which might have influenced their cytokine
balance. Further studies are needed to establish the im-
munologic effects of hydrocortisone therapy in HIE in-
fants undergoing intensive therapy. Finally, the relatively
low number of participants limits the direct clinical utility
of the assessment of the prevalence of CD4+ IL-1β+ and
CD4+ IL-1β+ CD49d+ cells at 6 h as a predictive marker
for the severity of the insult at an early stage in asphyxia.
Conclusion
In conclusion, the need for more specific prognostic
markers other than clinical assessment in neonatal as-
phyxia is clear, since clinical signs often do not correlate
with neurological outcome and do not enable differenti-
ation between moderate and severe hypoxic-ischemic
encephalopathy. The role of various cytokines in neuroin-
flammation following hypoxic-ischemic injury is
supported by a rapidly expanding body of evidence. IL-1β
and IL-6 appear to play a key role in the early events of
the inflammatory response, while TNF-α seems to be re-
sponsible for triggering a prolonged inflammation, poten-
tially contributing to a worse outcome. On the other
hand, TGF-β has a compensatory role in decreasing the
Table 3 Summary of the proposed effects of distinct cytokines on the severity of neonatal asphyxia
Pro-inflammatory Anti-inflammatory
Contribution to better
outcome
IL-1β: rapid decrease, higher initial prevalence, and extravasation in
severe insult
G-CSF: rapid decrease in moderate insult, higher plasma levels in
severe insult
TGF-β: increased production and extravasation in
moderate insult
IDO: early compensation up to 1 week
Contribution to worse
outcome
TNF-α: elevated intracellular levels up to 1 month
IL-17: high prevalence in severe insult up to 1 month
IL-6: higher plasma levels in severe insult at 1 week, decrease in
moderate insult by 1 month
Treg: unremarkable difference at 24 h, not
upregulated
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level of inflammation from an early stage following the in-
sult (Table 3). Based on ROC analysis, the assessment of
the prevalence of CD4+ IL-1β+ and CD4+ IL-1β+ CD49d
+ cells at 6 h appears to be able to predict severity at an
early stage in asphyxia (Fig. 5). Our current results open a
potentially fruitful area of research as well as diagnostic
and therapeutic development in neonatal asphyxia.
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